V
Ventus Therapeutics
Biotech & Life Sciences · Montreal, Canada · Founded 2019
Applying structural immunology to discover and develop therapeutics targeting immune pathways to address human disease MoreLess
Ventus Therapeutics is a clinical-stage biopharmaceutical startup that operates in the healthcare sector, specifically in the fields of immunology, inflammation, and neurology. The company is currently working on developing a pipeline of innovative medicines, with its most advanced program, VENT-02, being a brain-penetrant NLRP3 inhibitor currently in Phase 1. In simpler terms, this means that the company is in the early stages of testing a new drug that can penetrate the brain and inhibit a protein involved in inflammation and immune response.
The company's business model revolves around the research, development, and eventual commercialization of these novel medicines. Their primary clients are likely to be healthcare providers and patients suffering from conditions related to immunology, inflammation, and neurology. The company generates revenue through the successful development and sale of its pharmaceutical products.
Ventus Therapeutics places a strong emphasis on its team, believing in the power of innovative solutions to solve complex problems. They are continually seeking talented individuals to join their team and contribute to their scientific pursuits.
Keywords: Biopharmaceutical, Clinical-Stage, Immunology, Inflammation, Neurology, Drug Development, NLRP3 Inhibitor, Healthcare, Research and Development, Innovative Solutions.
Company overview
Ventus Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2019
- Headquarters
- Montreal, Canada
- Employees
- 56
- Open positions
- None listed
- Dealroom signal
- 28.0
Valuation & funding
Ventus Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Apr 2023 | $150K | — | Michael J. Fox Foundation for Parkinson's Research | ↗ |
| LATE VCOther financing | Sep 2022 | $70M | $280M | Novo Nordisk | ↗ |
| SERIES COther financing | Feb 2022 | $140M | $560M | Qatar Investment Authority · SoftBank · Versant Ventures · Fonds de solidarité FTQ | ↗ |
| SERIES BOther financing | Apr 2021 | $100M | $400M | Versant Ventures · Alexandria Venture Investments · Casdin Capital · BVF Partners | ↗ |
| SERIES AOther financing | May 2020 | $60M | $240M | Versant Ventures | ↗ |
Growth signals
Ventus Therapeutics website traffic
Latest recorded traffic for Ventus Therapeutics is 7.5K monthly website visits, up 19% over the last three months. Ventus Therapeutics's team declined 23.3% over the past year.
Comparisons
Ventus Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Ventus Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Ventus Therapeutics has talent and traffic
team presence
In the news
Latest news about Ventus Therapeutics
Recent press, funding announcements, and product moves mentioning Ventus Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Ventus Therapeutics
An AI-synthesized read of the highest-engagement posts about Ventus Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ventus Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.